Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
genital herpes market insight epidemiology and market forecast

SALE

Genital Herpes - Market Insight, Epidemiology and Market Forecast - 2028

Published Date : 2019

Pages : 148

Region : United States, Japan, EU4 & UK

SALE

Summary
TOC Table of Content
LOT
- Sample Request

genital herpes market insight epidemiology and market forecast

DelveInsight's 'Genital Herpes - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Genital Herpes in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Genital Herpes from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

Study Period: 2017-2028

Genital Herpes - Disease Understanding and Treatment Algorithm

Genital Herpes is a sexually transmitted disease (STD) caused by the herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2), where HSV is the leading cause of genital ulcers. HSV-1 is commonly found around the mouth (cold sores) and typically causes non-sexually transmitted oral herpes infection. HSV-1 commonly causes labial or pharyngeal infection, and transmission is primarily by non-genital contact. Though HSV-1 can also be transmitted to the genitals through oral sex, infections with HSV-1 can also happen from general interactions such as: eating from the same utensils; sharing lip balm or kissing.

HSV-2 typically affects the genital area and is transmitted by intimate sexual contact. HSV-2 infection is lifelong and incurable and is of particular concern due to its epidemiological synergy with HIV infection and transmission. People who are infected with HSV-2 are approximately three times more likely to become infected with HIV, and people with both HIV and genital HSV are more likely to transmit the infection to others. HSV-2 is contracted through forms of sexual contact with a person who has HSV-2. While HSV-2 infections spread through contact with a herpes sore, the AAD reports that most people contract HSV-1 from an infected person who is asymptomatic or does not have sores.

The DelveInsight Genital Herpes market report gives a thorough understanding of the Genital Herpes by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Genital Herpes in the US, Europe, and Japan.

Genital Herpes Epidemiology

The Genital Herpes epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by prevalent population, gender-specific prevalent population and diagnosed cases of Genital Herpes.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the prevalent population of Genital Herpes was estimated to be 83,782,625 [7MM] in 2018. United States accounts for the highest Genital Herpes cases, followed by EU5 (Germany, France, Italy, Spain and UK) and Japan. Among the EU5 countries Germany had the highest prevalent patient population of Genital Herpes, followed by France.

Genital Herpes Drug Chapters

This segment of the Genital Herpes report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

There are currently three FDA approved anti-viral therapies including Acyclovir, Famciclovir and Valacyclovir, which are being used for the treatment of Genital herpes in the United States. However these drugs have shown to be effective in managing the Genital Herpes frequent recurrence and healing of lesions but they are not fully potent in clearing the underline HSV infection. Also these drugs are associated with certain toxicity and subsequently virus are developing resistance against the existing batch of antivirals highlighting the need of innovative drugs. Curative drugs and vaccines remains one of the major unmet medical need in this space. Detailed chapters for all of these marketed drugs along with late phase promising candidates like Pritelivir and GEN-003 have been covered in the report.

Genital Herpes Market Outlook

The Genital Herpes market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the global market of Genital Herpes was estimated to be USD 1,211.3 million in 2018. The United States accounts for the largest market size of Genital Herpes, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.

The dynamics of Genital Herpes market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period 2019-2028. Launch of potential therapies may increase market size in the coming years, assisted by an increase in diagnosed prevalent population of Genital Herpes. Upcoming therapies such as Pritelivir (Aicuris) and GEN-003 (Genocea), have the potential to create a significant positive shift in the Genital Herpes market size. The United States accounts for the largest market size of Genital Herpes, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.

Genital Herpes Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The market size of Genital Herpes includes the drug-uptake for individual therapies, which is further segmented on the basis of market size and market share by Line of therapy and Route of Administration.

To counter current unmet needs of the market and to provide better treatment options for Genital Herpes, several companies are working robustly on developing new therapies with novel mechanism of action.

Genital Herpes Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

Genital Herpes Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition

Genital Herpes Report Assessment

• Current Treatment Practices

• Unmet Needs

• Detailed Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Genital Herpes market.

• Organize sales and marketing efforts by identifying the best opportunities for Genital Herpes market.

• To understand the future market competition in the Genital Herpes market.

1. Key Insights

2. Genital Herpes Market Overview at a Glance

2.1 Market Share (%) Distribution of Genital Herpes in 2017

2.2 Market Share (%) Distribution of Genital Herpes in 2027

3 Disease Background and Overview: Genital Herpes

3.1 Introduction

3.2 Causes

3.2.1 Viral Transmission and Infection

3.3 Pathophysiology

3.4 Risk factors

3.5 Complications

3.6 Signs and Symptoms

3.7 Clinical Manifestations

3.8 Diagnosis

4 Diagnostic Algorithm

5 Epidemiology and Patient Population

5.1 Key Findings

5.2 Disease Definition

5.3 Population and Forecast Parameters

5.4 7MM Prevalent Population of Genital Herpes

6 Country Wise-Epidemiology of Genital Herpes

6.1 United States

6.1.1 Prevalent Population of Genital Herpes

6.1.2 Gender Specific Prevalent Population of Genital Herpes

6.1.3 Total Diagnosed Cases of Genital Herpes

6.2 Germany

6.2.1 Prevalent Population of Genital Herpes

6.2.2 Gender Specific Prevalent Population of Genital Herpes

6.2.3 Total Diagnosed Cases of Genital Herpes

6.3 France

6.3.1 Prevalent Population of Genital Herpes

6.3.2 Gender Specific Prevalent Population of Genital Herpes

6.3.3 Total Diagnosed Cases of Genital Herpes

6.4 United Kingdom

6.4.1 Prevalent Population of Genital Herpes

6.4.2 Gender Specific Prevalent Population of Genital Herpes

6.4.3 Total Diagnosed Cases of Genital Herpes

6.5 Italy

6.5.1 Prevalent Population of Genital Herpes

6.5.2 Gender Specific Prevalent Population of Genital Herpes

6.5.1 Diagnosed Cases of Genital Herpes

6.6 Spain

6.6.1 Prevalent Population of Genital Herpes

6.6.2 Gender Specific Prevalent Population of Genital Herpes

6.6.3 Diagnosed Cases of Genital Herpes

6.7 Japan

6.7.1 Prevalent Population of Genital Herpes

6.7.1.1 Prevalent Population of Genital Herpes

6.7.2 Gender Specific Prevalent Population of Genital Herpes

6.7.3 Diagnosed Cases of Genital Herpes

7 Current Treatment and Medical Practices

7.1 Treatment of drug-resistant Genital Herpes Simplex Virus Infection in HIV-infected patients

7.2 Management

7.3 Treatment Guidelines

7.3.1 Centers for Disease Control and Prevention (CDC): Guidelines for the treatment of Genital Herpes

7.3.2 World Health Organization (WHO): Recommendations for Genital Herpes Simplex Virus

7.3.3 European Guidelines for Management of Genital Herpes

8 Treatment Algorithm

9 Unmet Needs

10 Marketed drugs

10.1 Famvir: Novartis

10.1.1 Drug Description

10.1.1 Other development activities

10.1.2 Regulatory Milestones

10.1.3 Advantages & Disadvantages

10.1.4 Safety and Efficacy

10.1.5 Product Profile

10.2 Valtrex: GlaxoSmithKline

10.2.1 Drug Description

10.2.2 Regulatory Milestones

10.2.3 Advantages & Disadvantages

10.2.4 Safety and Efficacy

10.2.5 Product Profile

10.3 Zovirax: GlaxoSmithKline

10.3.1 Drug Description

10.3.2 Regulatory Milestones

10.3.3 Advantages & Disadvantages

10.3.4 Safety and Efficacy

10.3.5 Product Profile

11 Emerging Drugs

Key Cross Competition 101

11.1 GEN 003: Genocea Biosciences

11.1.1 Product Description

11.1.2 Other Development Activities

11.1.3 Clinical Development

11.1.4 Clinical Trials Information

11.1.5 Safety and Efficacy

11.1.6 Advantages and Disadvantages

11.1.7 Product Profile

11.2 Pritelivir: AiCuris

11.2.1 Other development activities

11.2.2 Clinical Development

11.2.3 Clinical Trials Information

11.2.4 Safety and Efficacy

11.2.5 Advantages and Disadvantages

11.2.6 Product Profile

11.3 M5210B: Maruho

11.3.1 Product Profile

12 Genital Herpes: 7 Major Market Analysis

12.1 Market Size of Genital Herpes in 7MM

12.2 Genital Herpes Market by Treatment Types

12.3 Emerging Therapies Market of Genital Herpes

13 Market Outlook by Country

13.1 The United States: Market Outlook

13.1.1 United States Market Size

13.1.1.1 Total Market size of Genital Herpes

13.1.1.2 Genital Herpes Market by Treatment Types

13.1.1.3 Market Size by Emerging Therapies

13.2 EU-5 Countries: Market Outlook

13.2.1 Germany

13.2.1.1 Total Market size of Genital Herpes

13.2.1.2 Genital Herpes Market by Treatment Types

13.2.1.3 Market Size by Emerging Therapies

13.2.2 France

13.2.2.1 Total Market size of Genital Herpes

13.2.2.2 Genital Herpes Market by Treatment Types

13.2.2.3 Market Size by Emerging Therapies

13.2.3 United Kingdom

13.2.3.1 Total Market size of Genital Herpes

13.2.3.2 Genital Herpes Market by Treatment Types

13.2.3.3 Market Size by Emerging Therapies

13.2.4 Spain

13.2.4.1 Total Market size of Genital Herpes

13.2.4.2 Genital Herpes Market by Treatment Types

13.2.4.3 Market Size by Emerging Therapies

13.2.5 Italy

13.2.5.1 Total Market size of Genital Herpes

13.2.5.2 Genital Herpes Market by Treatment Types

13.2.5.3 Market Size by Emerging Therapies

13.3 Japan: Market Outlook

13.3.1 Total Market size of Genital Herpes

13.3.2 Genital Herpes Market by Treatment Types

13.3.3 Market Size by Emerging Therapies

14. Market Drivers

15.Market Barriers

16. Appendix

16.1 Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

List of Tables:

Table 1: List of HSV glycoproteins and their reported functions

Table 2: Details of grade of recommendation and equivalent evidence level

Table 3: Methods to detect HSV and HSV-specific antibody

Table 4: Methods to detect HSV and HSV-specific antibody

Table 5: Prevalent Population of Genital Herpes in the 7MM (2016-2027)

Table 6: Total Prevalent Population of Genital Herpes in the United States (2016-2027)

Table 7: Gender-Specific Prevalent Population of Genital Herpes in the United States (2016-2027)

Table 8: Total Diagnosed Cases of Genital Herpes in the United States (2016-2027)

Table 9: Total Prevalent Population of Genital Herpes in Germany (2016-2027)

Table 10: Gender-Specific Prevalent Population of Genital Herpes in Germany (2016-2027)

Table 11: Total Diagnosed Cases of Genital Herpes in the Germany (2016-2027)

Table 12: Prevalent Population of Genital Herpes in France (2016-2027)

Table 13: Gender-Specific Prevalent Population of Genital Herpes in France (2016-2027)

Table 14: Total Diagnosed Cases of Genital Herpes in the France (2016-2027)

Table 15: Prevalent Population of Genital Herpes from HSV-1 in the United Kingdom (2016-2027)

Table 16: Gender-Specific Prevalent Population of Genital Herpes in the United Kingdom (2016-2027)

Table 17: Total Diagnosed Cases of Genital Herpes in the United Kingdom (2016-2027)

Table 18: Prevalent Population of Genital Herpes in Italy (2016-2027)

Table 19: Gender-Specific Prevalent Population of Genital Herpes in Italy (2016-2027)

Table 20: Diagnosed Cases of Genital Herpes in Italy (2016-2027)

Table 21: Prevalent Population of Genital Herpes in Spain (2016-2027)

Table 22: Gender-Specific Prevalent Population of Genital Herpes from in Spain (2016-2027)

Table 23: Diagnosed Cases of Genital Herpes in Spain (2016-2027)

Table 24: Prevalent Population of Genital Herpes in Japan (2016-2027)

Table 25: Gender-Specific Prevalent Population of Genital Herpes in Japan (2016-2027)

Table 26: Diagnosed Cases of Genital Herpes in Japan (2016-2027)

Table 27: Dosage of Aciclovir for Genital Herpes

Table 28: Indications for Aciclovir Therapy

Table 29: Dosage of Famciclovir for Genital Herpes

Table 30: Dosage of Valaciclovir for Genital Herpes

Table 31: Standard doses of antivirals against HSV according to indications

Table 32: Efficacy of Acyclovir, Valaciclovir, and Famciclovir in the treatment of genital HSV Disease

Table 33: Antiviral Agents for treatment of drug-resistant Genital Herpes Simplex Virus Infection in HIV-Infected patients

Table 34: Recommended Regimens for First Clinical Episode of Genital Herpes

Table 35: Recommended Suppressive Regimens for Treatment of Recurrent Genital Herpes

Table 36: Recommended Episodic Regimens for Treatment of Recurrent Genital Herpes

Table 37: Recommended Regimens for Suppressive Therapy of pregnant women with recurrent Genital Herpes *

Table 38: WHO Recommendations for treatment of Genital Herpes Simplex Virus

Table 39: European Guidelines for Management of Genital Herpes (2017)

Table 40: Comparison of emerging drugs under development (Phase II)

Table 28: GEN-003,Clinical Trial Description, 2018

Table 42: Pritelivir, Clinical Trial Description, 2018

Table 44: 7 Major Market Size of Genital Herpes in USD Million (2016-2027)

Table 45: 7MM Genital Herpes Market by Treatment types in USD Million (2016-2027)

Table 46: 7MM Emerging Therapies market size of Genital Herpes in USD Million (2016-2027)

Table 47: 7 Major Market Size of Genital Herpes in USD Million (2016-2027)

Table 48: The U.S. Genital Herpes Market by Treatment types in USD Million (2016-2027)

Table 49: Emerging Therapies market size of Genital Herpes in USD Million (2016-2027)

Table 50: Market Size of Genital Herpes in Germany, in USD Million (2016-2027)

Table 51: Genital Herpes Market by Treatment types in Germany, in USD Million (2016-2027)

Table 52: Emerging Therapies market of Genital Herpes in Germany, in USD Million (2016-2027)

Table 53: Market Size of Genital Herpes in France, in USD Million (2016-2027)

Table 54: Genital Herpes Market by Treatment types in France, in USD Million (2016-2027)

Table 55: Emerging Therapies market of Genital Herpes in France, in USD Million (2016-2027)

Table 56: Market Size of Genital Herpes in the UK, in USD Million (2016-2027)

Table 57: Genital Herpes Market by Treatment types in the UK, in USD Million (2016-2027)

Table 58: Emerging Therapies market of Genital Herpes in the UK, in USD Million (2016-2027)

Table 59: Market Size of Genital Herpes in Spain, in USD Million (2016-2027)

Table 60: Genital Herpes Market by Treatment types in Spain, in USD Million (2016-2027)

Table 61: Emerging Therapies market of Genital Herpes in Spain, in USD Million (2016-2027)

Table 62: Market Size of Genital Herpes in Italy, in USD Million (2016-2027)

Table 63: Genital Herpes Market by Treatment types in Italy, in USD Million (2016-2027)

Table 64: Emerging Therapies market of Genital Herpes in Italy, in USD Million (2016-2027)

Table 65: Market Size of Genital Herpes in Japan, in USD Million (2016-2027)

Table 66: Genital Herpes Market by Treatment types in Japan, in USD Million (2016-2027)

Table 67:Emerging Therapies market of Genital Herpes in Japan, in USD Million (2016-2027)

List of Figures:

Figure 1: Schematic of HSV-1/HSV-2 lytic infection

Figure 2: Schematic of Primary Infection and Reactivation

Figure 3: Signs and Symptoms of Genital Herpes

Figure 4: Diagnostic Algorithm for Genital Herpes

Figure 5: Prevalent Population of Genital Herpes in the 7MM (2016-2027)

Figure 6: Total Prevalent Population of Genital Herpes in the United States (2016-2027)

Figure 7: Gender-Specific Prevalent Population of Genital Herpes in the United States (2016-2027)

Figure 8: Total Diagnosed Cases of Genital Herpes in the United States (2016-2027)

Figure 9: Total Prevalent Population of Genital Herpes in Germany (2016-2027)

Figure 10: Gender-Specific Prevalent Population of Genital Herpes in Germany (2016-2027)

Figure 11: Total Diagnosed Cases of Genital Herpes in the Germany (2016-2027)

Figure 12: Prevalent Population of Genital Herpes in France (2016-2027)

Figure 13: Gender-Specific Prevalent Population of Genital Herpes in France (2016-2027)

Figure 14: Total Diagnosed Cases of Genital Herpes in the France (2016-2027)

Figure 15: Prevalent Population of Genital Herpes from HSV-1 in the United Kingdom (2016-2027)

Figure 16: Gender-Specific Prevalent Population of Genital Herpes in the United Kingdom (2016-2027)

Figure 17: Total Diagnosed Cases of Genital Herpes in the United Kingdom (2016-2027)

Figure 18: Prevalent Population of Genital Herpes in Italy (2016-2027)

Figure 19: Gender-Specific Prevalent Population of Genital Herpes in Italy (2016-2027)

Figure 20: Diagnosed Cases of Genital Herpes in Italy (2016-2027)

Figure 21: Prevalent Population of Genital Herpes in Spain (2016-2027)

Figure 22: Gender-Specific Prevalent Population of Genital Herpes in Spain (2016-2027)

Figure 23: Diagnosed Cases of Genital Herpes in Spain (2016-2027)

Figure 24: Prevalent Population of Genital Herpes in Japan (2016-2027)

Figure 25: Gender-Specific Prevalent Population of Genital Herpes in Japan (2016-2027)

Figure 26: Diagnosed Cases of Genital Herpes in Japan (2016-2027)

Figure 27: Treatment Algorithm of Genital Herpes

Figure 28 : Activation of Aciclovir

Figure 29: Mechanisms of action of Anti-Herpes Simplex Virus Antiviral drugs

Figure 30: Algorithm for the treatment of Herpes in Immunocompromised Individuals.

Figure 31: Unmet Needs of Genital Herpes

Figure 32: 7 Major Market Size of Genital Herpes in USD Million (2016-2027)

Figure 33: 7MM Genital Herpes Market by Treatment types in USD Million (2016-2027)

Figure 34: 7MM Emerging Therapies market size of Genital Herpes in USD Million (2016-2027)

Figure 35: Market Size of Genital Herpes in the United States, USD Millions (2016-2027)

Figure 36: The U.S. Genital Herpes Market by Treatment types in USD Million (2016-2027)

Figure 37: The U.S. Emerging Therapies market size of Genital Herpes in USD Million (2016-2027)

Figure 38: Market Size of Genital Herpes in Germany, USD Millions (2016-2027)

Figure 39: Genital Herpes Market by Treatment types in Germany, in USD Million (2016-2027)

Figure 40: Emerging Therapies market of Genital Herpes in Germany, in USD Million (2016-2027)

Figure 41: Market Size of Genital Herpes in France, USD Millions (2016-2027)

Figure 42: Genital Herpes Market by Treatment types in France, in USD Million (2016-2027)

Figure 43: Emerging Therapies market of Genital Herpes in France, in USD Million (2016-2027)

Figure 44: Market Size of Genital Herpes in the UK, USD Millions (2016-2027)

Figure 45: Genital Herpes Market by Treatment types in the UK, in USD Million (2016-2027)

Figure 46: Emerging Therapies market of Genital Herpes in the UK, in USD Million (2016-2027)

Figure 47: Market Size of Genital Herpes in Spain, USD Millions (2016-2027)

Figure 48: Genital Herpes Market by Treatment types in Spain, in USD Million (2016-2027)

Figure 49: Emerging Therapies market of Genital Herpes in Spain, in USD Million (2016-2027)

Figure 50: Market Size of Genital Herpes in Italy, USD Millions (2016-2027)

Figure 51: Genital Herpes Market by Treatment types in Italy, in USD Million (2016-2027)

Figure 52: Emerging Therapies market of Genital Herpes in Italy, in USD Million (2016-2027)

Figure 53: Market Size of Genital Herpes in Japan, USD Millions (2016-2027)

Figure 54: Genital Herpes Market by Treatment types in Japan, in USD Million (2016-2027)

Figure 55: Emerging Therapies market of Genital Herpes in Japan, in USD Million (2016-2027)

Figure 56: Market Drivers

Figure 57:Market Barriers

Tags:

License Type

Offer